Plain-English translation of NCT06844357 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a new treatment called , given as an injection directly into the blood vessels feeding a liver tumor followed by a procedure to block those vessels, works better than the current standard treatment. The standard treatment uses a chemotherapy drug combined with the same vessel-blocking procedure. Researchers want to see if offers patients better results and fewer side effects.
Intermediate-stage liver cancer is a challenging disease, and while the current treatment helps many patients, doctors are looking for options that might work even better. This medication represents a new approach that may improve how well the treatment works or reduce harmful side effects.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive either the new treatment or the standard chemotherapy treatment. Both involve a minimally invasive procedure where doctors inject medication directly into the blood vessels supplying your tumor, then block those vessels to cut off the tumor's blood supply. You will have follow-up visits to monitor how well the treatment is working and check for any side effects. The trial involves about 300 patients across multiple medical centers.
AI-generated summary from trial data · Jun 25, 2026 · Not medical advice
China